院外心脏骤停后脑死亡的预测:心脏骤停后脑死亡评分的开发与验证
本研究基于两项院外心脏骤停(OHCA)试验的数据开发了心脏骤停后脑死亡(BDCA)评分,用于早期估计脑死亡风险。开发队列包括569例OHCA后24小时存活患者,其中84例(14.8%)发生脑死亡;独立预测因素包括女性(4分)、非可除颤心律(24分)、心脏病因(-6分)、神经病因(45分)、24小时血钠(mmol/L减140分)、入院时血管活性药物(4分)和24小时血管活性药物(6分)。BDCA评分在开发队列的AUC为0.82(95%CI 0.77-0.86),在验证队列(n=487)中AUC为0.81(95%CI 0.76-0.86)。验证队列中,评分<20、20-50和>50的患者脑死亡发生率分别为4.0%、20.4%和67.7%。该评分有助于早期发现脑死亡高风险患者,可能增加OHCA后的器官捐献。
要点
- BDCA评分基于OHCA后24小时内可用数据构建,用于早期估计脑死亡风险。
- 评分组成:女性4分,非可除颤心律24分,心脏病因-6分,神经病因45分,24小时血钠(mmol/L减140)分,入院时血管活性药物4分,24小时血管活性药物6分。
- 开发队列AUC 0.82(95%CI 0.77-0.86),验证队列AUC 0.81(95%CI 0.76-0.86)。
- 验证队列中评分<20、20-50、>50者脑死亡发生率分别为4.0%、20.4%、67.7%。
- BDCA评分可能有助于增加OHCA后的器官捐献。
适用人群与场景
- 院外心脏骤停(OHCA)后成功复苏且24小时存活的患者。
诊断标准与关键阈值
- BDCA评分:女性4分,非可除颤心律24分,心脏病因-6分,神经病因45分,24小时血钠(mmol/L减140)分,入院时血管活性药物4分,24小时血管活性药物6分。
- 评分<20分、20-50分、>50分对应验证队列脑死亡发生率4.0%、20.4%、67.7%。
研究设计与关键结果
- 开发队列包括569例OHCA后24小时存活患者,84例(14.8%)发生脑死亡。
- 独立预测因素:女性(4分)、非可除颤心律(24分)、心脏病因(-6分)、神经病因(45分)、24小时血钠(mmol/L减140分)、入院时血管活性药物(4分)、24小时血管活性药物(6分)。
- 开发队列AUC 0.82(95%CI 0.77-0.86),验证队列(n=487)AUC 0.81(95%CI 0.76-0.86)。
- 验证队列中评分<20、20-50、>50者脑死亡发生率分别为4.0%、20.4%、67.7%。
证据类型、等级与局限
- 研究类型:基于两项OHCA试验(Cyclosporine in Cardiac Arrest Resuscitation和Erythropoietin After OHCA)数据开发评分,并在另一大型前瞻性多中心数据集中验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- BDCA评分允许早期检测脑死亡高概率患者,可能有助于增加OHCA后的器官捐献。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Among patients successfully resuscitated after an out-of-hospital cardiac arrest (OHCA), 10% to 15% evolve toward brain death (BD), thus becoming potential organ donors.
RESEARCH QUESTION: Is it possible to establish a score for early estimation of BD risk after OHCA?
STUDY DESIGN AND METHODS: The BD after cardiac arrest (BDCA) score was developed from data available within 24 hours after OHCA from two OHCA trials: Cyclosporine in Cardiac Arrest Resuscitation and Erythropoietin After OHCA. The BDCA score was then validated in another large prospective multicenter data set. The main outcome was the occurrence of BD. Independent prognostic covariates for BD were identified using a binomial two-stage adaptive least absolute shrinkage and selection operator procedure.
RESULTS: The development cohort included 569 patients alive 24 hours after OHCA, among whom 84 (14.8%) experienced BD. Independent predictors of BD used to build the BDCA score were being female (4 points), nonshockable rhythm (24 points), cardiac cause of OHCA (-6 points), neurological cause of OHCA (45 points), natremia at 24 hours (natremia in millimoles per liter minus 140 points), and vasoactive drug at admission (4 points) and at 24 hours (6 points). The area under the curve (AUC) of the BDCA score was 0.82 (95% CI, 0.77-0.86), and the discrimination value in the validation cohort (n = 487) was consistent (AUC, 0.81; 95% CI, 0.76-0.86). In the validation cohort, BD occurred in 4.0%, 20.4%, and 67.7% of patients with scores of < 20, 20 to 50, and > 50, respectively.
INTERPRETATION: The BDCA score allows early detection of patients with a high probability of experiencing BD, which may help increase organ donation after OHCA.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01595958, and ClinicalTrials.gov; No.: NCT00999583; URL: www.clinicaltrials.gov.
参考来源
- Madelaine T, Cour M, Roy P, et al. Prediction of Brain Death After Out-of-Hospital Cardiac Arrest: Development and Validation of the Brain Death After Cardiac Arrest Score. Chest. 2021. PMID: 34116828. doi:10.1016/j.chest.2021.01.056
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。